乐普医疗 (300003.SZ) Latest Company News

Aug 28, 2026, 04:23 UTC
Lifetech Scientific reported a net loss of RMB 34.348 million for the six months ended June 2026, compared with a net profit of RMB 55.074 million a year earlier, with revenue down 11.2% year-on-year to RMB 601 million.
Source:
- aastocks.com
Aug 24, 2026, 08:24 UTC
Pu Zhongjie, actual controller and chairman of Lepu Medical, increased his stake in the company by 853,700 shares on August 24, 2026, representing 0.046% of total share capital, at an average price of 11.71 yuan per share.
Source:
- finance.sina.cn
Aug 21, 2026, 10:35 UTC
Lepu Medical director Wang Qihong resigned due to retirement, and Sun Lei was nominated to replace him as a non-independent director.
Source:
- finance.sina.cn
Aug 21, 2026, 10:34 UTC
Lepu Medical announced the transfer of its 54.2384% stake in Shanghai Minwei Biotechnology to its subsidiary Xintai Medical for 1.088 billion yuan, making Xintai Medical the controlling shareholder.
Source:
- finance.sina.cn
- aastocks.com
Aug 21, 2026, 10:33 UTC
Lepu Medical announced its 2026 first-half results: net profit attributable to shareholders was 499 million yuan, down 27.71% year-on-year; revenue was 3.214 billion yuan, down 4.61% year-on-year.
Source:
- finance.sina.cn
Aug 21, 2026, 10:33 UTC
Lepu Medical announced an interim cash dividend of 1.63 yuan per 10 shares (tax inclusive), based on 1.843 billion shares, with a total cash dividend of approximately 300 million yuan (tax inclusive).
Source:
- finance.sina.cn
Aug 17, 2026, 11:07 UTC
Lepu Medical's subsidiary Shanghai Minwei Biotechnology received approval from China's National Medical Products Administration to conduct clinical trials for its MWN117 injection, targeting overweight or obesity indications.
Source:
- finance.sina.cn
Aug 13, 2026, 08:55 UTC
Lepu Medical's shareholder 725 Institute plans to issue exchangeable bonds of up to 600 million yuan, backed by its shares in Lepu Medical.
Source:
- finance.sina.cn
Jul 2, 2026, 07:42 UTC
Lepu Medical's controlling shareholder Pu Zhongjie pledged 11.93 million shares on June 30 to secure debt repayment, and released 27.93 million shares from pledge on July 1.
Source:
- finance.sina.cn

300003.SZ

Lifetech Scientific reported a net loss of RMB 34.348 million for the six months ended June 2026, compared with a net profit of RMB 55.074 million a year earlier, with revenue down 11.2% year-on-year to RMB 601 million.

Pu Zhongjie, actual controller and chairman of Lepu Medical, increased his stake in the company by 853,700 shares on August 24, 2026, representing 0.046% of total share capital, at an average price of 11.71 yuan per share.

Lepu Medical director Wang Qihong resigned due to retirement, and Sun Lei was nominated to replace him as a non-independent director.

Lepu Medical announced the transfer of its 54.2384% stake in Shanghai Minwei Biotechnology to its subsidiary Xintai Medical for 1.088 billion yuan, making Xintai Medical the controlling shareholder.

Lepu Medical announced its 2026 first-half results: net profit attributable to shareholders was 499 million yuan, down 27.71% year-on-year; revenue was 3.214 billion yuan, down 4.61% year-on-year.

Lepu Medical announced an interim cash dividend of 1.63 yuan per 10 shares (tax inclusive), based on 1.843 billion shares, with a total cash dividend of approximately 300 million yuan (tax inclusive).

Lepu Medical's subsidiary Shanghai Minwei Biotechnology received approval from China's National Medical Products Administration to conduct clinical trials for its MWN117 injection, targeting overweight or obesity indications.

Lepu Medical's shareholder 725 Institute plans to issue exchangeable bonds of up to 600 million yuan, backed by its shares in Lepu Medical.

Lepu Medical's controlling shareholder Pu Zhongjie pledged 11.93 million shares on June 30 to secure debt repayment, and released 27.93 million shares from pledge on July 1.